EX-12.1 2 ex12_106302015.htm EXHIBIT 12.1 RATIO
Exhibit 12.1
 
Progenics Pharmaceuticals, Inc.
Ratio of Earnings (Loss) to Combined Fixed Charges and Preferred Stock Dividends
(in thousands)
 
 
  
Six Months
Ended
 June 30,
    
Years Ended December 31,
  
 
  
2015
    
2014
    
2013
    
2012
    
2011
    
2010
  
Determination of earnings (loss):
  
   
   
   
   
   
 
Income (loss) from operations
  
$
(21,951
)
  
$
4,410
 
  
$
(42,934
)
  
$
(35,431
 )   
$
10,381
 
  
$
(69,820
)
Add:
                                                
Fixed charges
    
181
      
373
      
710
      
410
      
695
      
709
  
 
                                                
Earnings (loss), as adjusted
    $
(21,770
)
  
$
4,783
 
  
$
(42,224
)
  
$
(35,021
 )   
$
11,076
 
  
$
(69,111
)
 
                                                
Fixed charges:
                                                
 
                                                
Estimate of interest within rental expense
    
181
      
373
      
710
      
410
      
695
      
709
  
 
                                                
Fixed charges
  
$
181
    
$
373
    
$
710
    
$
410
    
$
695
    
$
709
  
 
                                                
Preferred stock dividends
  
$
-
    
$
-
    
$
-
    
$
-
    
$
-
    
$
-
  
 
                                                
 
                                                
Ratio of earnings (loss) to fixed charges and preferred stock dividends
    
*
      
13
      
*
      
*
      
16
      
*
  
Coverage deficiency amount for total fixed charges and preferred stock dividends (1)
  
$
21,951
    
$
-
    
$
42,934
    
$
35,431
    
$
-
    
$
69,820
  

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1)
For the years ended 2010, 2012, 2013 and for the six months ended June 30, 2015, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.